JP2021535209A5 - - Google Patents

Info

Publication number
JP2021535209A5
JP2021535209A5 JP2021534405A JP2021534405A JP2021535209A5 JP 2021535209 A5 JP2021535209 A5 JP 2021535209A5 JP 2021534405 A JP2021534405 A JP 2021534405A JP 2021534405 A JP2021534405 A JP 2021534405A JP 2021535209 A5 JP2021535209 A5 JP 2021535209A5
Authority
JP
Japan
Prior art keywords
formula
peptide compound
seq
use according
cancer cells
Prior art date
Application number
JP2021534405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535209A (ja
JP7592320B2 (ja
JPWO2020037434A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2019/051170 external-priority patent/WO2020037434A1/en
Publication of JP2021535209A publication Critical patent/JP2021535209A/ja
Publication of JP2021535209A5 publication Critical patent/JP2021535209A5/ja
Publication of JPWO2020037434A5 publication Critical patent/JPWO2020037434A5/ja
Application granted granted Critical
Publication of JP7592320B2 publication Critical patent/JP7592320B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021534405A 2018-08-24 2019-08-26 ソルチリン受容体を標的化し血管擬態を阻害するための方法及び化合物 Active JP7592320B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862722726P 2018-08-24 2018-08-24
US62/722,726 2018-08-24
US201962804063P 2019-02-11 2019-02-11
US62/804,063 2019-02-11
PCT/CA2019/051170 WO2020037434A1 (en) 2018-08-24 2019-08-26 Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry

Publications (4)

Publication Number Publication Date
JP2021535209A JP2021535209A (ja) 2021-12-16
JP2021535209A5 true JP2021535209A5 (https=) 2022-08-29
JPWO2020037434A5 JPWO2020037434A5 (https=) 2022-08-29
JP7592320B2 JP7592320B2 (ja) 2024-12-02

Family

ID=69591094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534405A Active JP7592320B2 (ja) 2018-08-24 2019-08-26 ソルチリン受容体を標的化し血管擬態を阻害するための方法及び化合物

Country Status (8)

Country Link
US (1) US20220000971A1 (https=)
EP (1) EP3844190A4 (https=)
JP (1) JP7592320B2 (https=)
CN (1) CN113286820B (https=)
AU (1) AU2019324747A1 (https=)
CA (1) CA3110414A1 (https=)
IL (1) IL281043A (https=)
WO (1) WO2020037434A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107708733B (zh) 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
CA3006313C (en) 2015-11-24 2020-02-11 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
TWI809147B (zh) 2018-07-13 2023-07-21 美商阿列克特有限責任公司 抗分揀蛋白抗體及其使用方法
CN116731113A (zh) * 2022-03-01 2023-09-12 上海智肽生物科技有限公司 针对sort1的多肽化合物及其药物偶联物
CN119403786A (zh) 2022-06-23 2025-02-07 德罗普尼尔生物有限公司 选择性诱导细胞外靶标在溶酶体中降解的双功能分子
CN120641133A (zh) * 2022-11-14 2025-09-12 瑟瑞技术公司 用于刺激抗肿瘤免疫应答的药物缀合物化合物
WO2025054707A1 (en) * 2023-09-11 2025-03-20 Theratechnologies Inc. Peptide conjugates of camptothecin analogs and uses thereof
WO2025208212A1 (en) * 2024-04-02 2025-10-09 Theratechnologies Inc. Combination therapies comprising peptide-drug conjugates targeting sortilin
WO2025236098A1 (en) * 2024-05-16 2025-11-20 Theratechnologies Inc. Peptide conjugates of maytansinoids and uses thereof
WO2026021513A1 (zh) * 2024-07-25 2026-01-29 上海湃鸿生物科技有限公司 一种多肽药物偶联物及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016270874B2 (en) * 2015-06-03 2018-12-06 Tairx, Inc. Novel use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry
CA3006313C (en) * 2015-11-24 2020-02-11 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy

Similar Documents

Publication Publication Date Title
JP2021535209A5 (https=)
JP2019501141A5 (https=)
ES2882634T3 (es) Compuestos peptídicos y conjugados con péptidos para el tratamiento del cáncer mediante quimioterapia mediada por receptores
JP7592320B2 (ja) ソルチリン受容体を標的化し血管擬態を阻害するための方法及び化合物
CN102762586B (zh) 治疗肽
CN106132959B (zh) 用于缀合的细胞毒性微管溶素化合物
JP2020515578A5 (https=)
CA3067311A1 (en) Cd38 antibody drug conjugate
CN103044521B (zh) 天冬氨酸酶靶向激活的阿霉素衍生物、其制备方法和用途
CN112386707B (zh) 一种肿瘤靶向多肽药物偶联物及其制备方法
CN107849090A (zh) 抗体药物偶联物
ITMI20100093A1 (it) Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico
KR102224965B1 (ko) 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
RU2014134409A (ru) Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
JP2020508985A5 (https=)
JP2018509394A5 (https=)
JP2012505922A5 (https=)
CN102036676A (zh) 新颖的双重靶向性抗肿瘤轭合物
JPWO2020037434A5 (https=)
BG65926B1 (bg) Кахалалидни съединения
JP2019535702A (ja) ジンセンチド及びジンセンチド様ペプチドの調製及び使用
KR20210125484A (ko) 항체 약물 결합체에 사용되는 약물-링커 mc-mmaf의 제조 방법 및 이의 중간체
JP2023505509A (ja) ポリエチレングリコール複合薬、ならびにその調製方法およびその使用
WO2018069851A2 (en) C-met antibody drug conjugate
KR20230167033A (ko) 암 줄기 세포를 표적화하기 위한 방법 및 소르틸린 결합 접합체 화합물